Tempest Therapeutics (NASDAQ:TPST) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Tempest Therapeutics (NASDAQ:TPST) from a sell rating to a hold rating in a research report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Wednesday. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $30.00.

Tempest Therapeutics Stock Down 4.7%

Shares of Tempest Therapeutics stock opened at $10.27 on Friday. Tempest Therapeutics has a twelve month low of $5.33 and a twelve month high of $20.67. The stock has a market cap of $45.60 million, a price-to-earnings ratio of -0.70 and a beta of -2.08. The company’s fifty day moving average is $9.78 and its 200 day moving average is $8.08.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings data on Monday, August 11th. The company reported ($2.07) earnings per share for the quarter, topping the consensus estimate of ($3.23) by $1.16. As a group, equities analysts anticipate that Tempest Therapeutics will post -1.39 earnings per share for the current fiscal year.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.